BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2:52-62. [PMID: 28404015 DOI: 10.1016/s2468-1253(16)30080-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
2 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [DOI: 10.3748/wjg.v27.i40.6861] [Reference Citation Analysis]
3 Mohd Suan MA, Said SM, Lim PY, Azman AZF, Abu Hassan MR. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study. PLoS One 2019;14:e0224459. [PMID: 31661525 DOI: 10.1371/journal.pone.0224459] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Yamamoto C, Nagashima S, Isomura M, Ko K, Chuon C, Akita T, Katayama K, Woodring J, Hossain MS, Takahashi K, Tanaka J. Evaluation of the efficiency of dried blood spot-based measurement of hepatitis B and hepatitis C virus seromarkers. Sci Rep 2020;10:3857. [PMID: 32123234 DOI: 10.1038/s41598-020-60703-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
5 Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, Yu ML, Yuen MF. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. Clin Mol Hepatol 2020;26:554-61. [PMID: 32854457 DOI: 10.3350/cmh.2020.0058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yoo ER, Perumpail RB, Cholankeril G, Jayasekera CR, Ahmed A. Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals. J Clin Transl Hepatol 2017;5:130-3. [PMID: 28660150 DOI: 10.14218/JCTH.2016.00059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
7 Shen C, Ge Z, Dong C, Wang C, Shao J, Cai W, Huang P, Fan H, Li J, Zhang Y, Yue M. Genetic Variants in KIR/HLA-C Genes Are Associated With the Susceptibility to HCV Infection in a High-Risk Chinese Population. Front Immunol 2021;12:632353. [PMID: 34220799 DOI: 10.3389/fimmu.2021.632353] [Reference Citation Analysis]
8 Seo HY, Seo MS, Yoon SY, Choi JW, Ko SY. Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis. Korean J Intern Med 2020;35:559-65. [PMID: 31064176 DOI: 10.3904/kjim.2018.338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Wei B, Ji F, Yeo YH, Ogawa E, Zou B, Stave CD, Dang S, Li Z, Furusyo N, Cheung RC, Nguyen MH. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2018;5:e000207. [PMID: 30002863 DOI: 10.1136/bmjgast-2018-000207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH;  REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587-598. [PMID: 31463665 DOI: 10.1007/s12072-019-09974-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
11 Huang YC, Huang CF, Liu SF, Liu HY, Yeh ML, Huang CI, Hsieh MH, Dai CY, Chen SC, Yu ML, Chuang WL, Huang JF. The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. PLoS One 2021;16:e0246376. [PMID: 33513184 DOI: 10.1371/journal.pone.0246376] [Reference Citation Analysis]
12 Zheng Y, Wu J, Ding C, Xu K, Yang S, Li L. Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study. Virol J 2020;17:132. [PMID: 32859216 DOI: 10.1186/s12985-020-01393-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
13 Liu Y, Wang Z, Tobe RG, Lin H, Wu B. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b. Clin Drug Investig. 2018;38:427-437. [PMID: 29417464 DOI: 10.1007/s40261-018-0621-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
14 Wong YJ, Cheen MH, Hsiang JC, Kumar R, Tan J, Teo EK, Thurairajah PH. Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. JGH Open 2019;3:210-6. [PMID: 31276038 DOI: 10.1002/jgh3.12139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018; 6(13): 589-599 [PMID: 30430114 DOI: 10.12998/wjcc.v6.i13.589] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 71] [Article Influence: 31.7] [Reference Citation Analysis]
16 Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis 2019;21:e13047. [PMID: 30615227 DOI: 10.1111/tid.13047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
18 Paboriboune P, Vial T, Sitbounlang P, Bertani S, Trépo C, Dény P, Babin FX, Steenkeste N, Pineau P, Deharo E. Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients. Virol Sin 2018;33:295-303. [PMID: 29948850 DOI: 10.1007/s12250-018-0039-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Dar FS, Bhatti ABH, Qureshi AI, Khan NY, Eswani Z, Zia HH, Khan EU, Khan NA, Rana A, Shah NH, Salih M, Nazer R. Living Donor Liver Transplantation in South Asia: Single Center Experience on Intermediate-Term Outcomes. World J Surg 2018;42:1111-9. [PMID: 28936685 DOI: 10.1007/s00268-017-4259-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
20 Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. Eur J Drug Metab Pharmacokinet 2019;44:43-52. [PMID: 29909549 DOI: 10.1007/s13318-018-0492-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Chang YK, Tseng YT, Chen KH, Chen KT. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan. BMC Endocr Disord 2019;19:36. [PMID: 30953492 DOI: 10.1186/s12902-019-0362-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, Omata M, Ooka Y, Han KH, Lee HW, Jafri W, Butt AS, Chong CH, Lim SG, Pwu RF, Chen DS. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167-228. [PMID: 31852635 DOI: 10.1016/s2468-1253(19)30342-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 37] [Article Influence: 29.0] [Reference Citation Analysis]